Actavis Inc. Submits Supplement for Gemcitabine Hydrochloride (ANDA204549)
Actavis Inc. has submitted a supplemental application for Gemcitabine Hydrochloride under ANDA204549, which is currently under standard review.
Asset / Drug
Drug and asset intelligence for Actavis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Chemotherapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.